WO2010064714A1 - 栄養組成物 - Google Patents
栄養組成物 Download PDFInfo
- Publication number
- WO2010064714A1 WO2010064714A1 PCT/JP2009/070432 JP2009070432W WO2010064714A1 WO 2010064714 A1 WO2010064714 A1 WO 2010064714A1 JP 2009070432 W JP2009070432 W JP 2009070432W WO 2010064714 A1 WO2010064714 A1 WO 2010064714A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nutritional composition
- composition according
- group
- fatty acids
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 174
- 235000015097 nutrients Nutrition 0.000 title abstract description 9
- 208000017169 kidney disease Diseases 0.000 claims abstract description 101
- 206010061218 Inflammation Diseases 0.000 claims abstract description 53
- 230000004054 inflammatory process Effects 0.000 claims abstract description 53
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 51
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 50
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims abstract description 48
- 229940033080 omega-6 fatty acid Drugs 0.000 claims abstract description 47
- 150000002632 lipids Chemical class 0.000 claims abstract description 42
- 229940024606 amino acid Drugs 0.000 claims abstract description 41
- 150000001413 amino acids Chemical class 0.000 claims abstract description 41
- 208000002720 Malnutrition Diseases 0.000 claims abstract description 38
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 37
- 208000024891 symptom Diseases 0.000 claims abstract description 35
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 34
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 31
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 31
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 30
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 30
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 29
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 29
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 29
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 29
- 229960000310 isoleucine Drugs 0.000 claims abstract description 29
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 29
- 230000036542 oxidative stress Effects 0.000 claims abstract description 28
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 27
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000004474 valine Substances 0.000 claims abstract description 27
- 235000000824 malnutrition Nutrition 0.000 claims abstract description 22
- 230000001071 malnutrition Effects 0.000 claims abstract description 22
- 208000015380 nutritional deficiency disease Diseases 0.000 claims abstract description 22
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 6
- 235000016709 nutrition Nutrition 0.000 claims description 136
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 35
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 35
- 230000006872 improvement Effects 0.000 claims description 32
- 230000005856 abnormality Effects 0.000 claims description 31
- 229940001941 soy protein Drugs 0.000 claims description 31
- 230000002265 prevention Effects 0.000 claims description 30
- 229960002885 histidine Drugs 0.000 claims description 29
- 229960003136 leucine Drugs 0.000 claims description 28
- 229960004295 valine Drugs 0.000 claims description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 230000003449 preventive effect Effects 0.000 claims description 24
- 235000018102 proteins Nutrition 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 239000006014 omega-3 oil Substances 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 17
- 239000000194 fatty acid Substances 0.000 claims description 17
- 229930195729 fatty acid Natural products 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 17
- 150000004665 fatty acids Chemical class 0.000 claims description 16
- 235000000112 undernutrition Nutrition 0.000 claims description 15
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- 229910052711 selenium Inorganic materials 0.000 claims description 12
- 239000011669 selenium Substances 0.000 claims description 12
- 235000019154 vitamin C Nutrition 0.000 claims description 12
- 239000011718 vitamin C Substances 0.000 claims description 12
- 230000035764 nutrition Effects 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 235000019165 vitamin E Nutrition 0.000 claims description 10
- 229940046009 vitamin E Drugs 0.000 claims description 10
- 239000011709 vitamin E Substances 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 7
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 7
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 7
- 229940124375 agent for diabetic nephropathy Drugs 0.000 claims description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 4
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 4
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- 235000021342 arachidonic acid Nutrition 0.000 claims description 4
- 229940114079 arachidonic acid Drugs 0.000 claims description 4
- 235000014304 histidine Nutrition 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 4
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 3
- 229960002733 gamolenic acid Drugs 0.000 claims description 3
- 230000006371 metabolic abnormality Effects 0.000 claims description 3
- 235000014705 isoleucine Nutrition 0.000 claims 3
- 235000005772 leucine Nutrition 0.000 claims 3
- 235000014393 valine Nutrition 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 25
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 239000000413 hydrolysate Substances 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 33
- 235000013305 food Nutrition 0.000 description 20
- 108010074051 C-Reactive Protein Proteins 0.000 description 17
- 102100032752 C-reactive protein Human genes 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 16
- 238000000502 dialysis Methods 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- -1 gums Substances 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000003907 kidney function Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 150000005693 branched-chain amino acids Chemical class 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000008214 LDL Cholesterol Methods 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000020124 milk-based beverage Nutrition 0.000 description 4
- 235000003715 nutritional status Nutrition 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 241000725101 Clea Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000021323 fish oil Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000021075 protein intake Nutrition 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 208000008425 Protein deficiency Diseases 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000020931 dietary conditions Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 2
- 229950000329 thiouracil Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 208000011514 Familial renal glucosuria Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010038548 Renal vein thrombosis Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940095686 granule product Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 208000007278 renal glycosuria Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a nutritional composition useful for patients with renal diseases, and more specifically, comprising a specific fatty acid and amino acid, or further soy protein, such as malnutrition, inflammation or arteriosclerosis associated with renal diseases.
- the present invention relates to a nutritional composition useful for prevention or improvement.
- Renal diseases include inflammatory kidney diseases such as nephritic syndrome and nephrotic syndrome, vascular disorder diseases such as atheroembolic kidney disease, renal vein thrombosis, and diabetic nephropathy caused by diabetes.
- malnutrition that is, malnutrition is often observed.
- Undernutrition is an important factor that affects the prognosis of patients with renal diseases.
- the kidney function is reduced due to insufficient blood flow to the kidney due to the disease, bleeding, heart failure, etc., urinary tract obstruction due to prostate enlargement, kidney damage, etc., it causes acute or chronic renal failure and maintains life Therefore, artificial dialysis may be necessary.
- Non-Patent Document 1 the current treatment method for these patients has not been established, and has been dealt with by performing optimal dialysis for each patient, that is, determining the optimal amount of dialysis and excluding endotoxin in the dialysate. There are only.
- Non-patent Document 2 the CRP concentration in blood decreased by administering a fish oil capsule containing 427 mg of eicosapentaenoic acid and 244 mg of docosahexaenoic acid for 12 weeks.
- the fish oil capsules do not contain protein and have not been improved in undernutrition.
- Non-patent Document 3 it has been reported that no reduction in CRP and improvement in nutritional status were observed.
- omega-3 fatty acids such as eicosapentaenoic acid have a problem in flavor, there is a concern that compliance may be lowered when a high concentration is added, and there is a possibility that bleeding tendency may appear due to its platelet aggregation inhibitory action. Should be considered. Therefore, omega-3 fatty acids alone cannot be expected to suppress inflammation and improve the nutritional status of dialysis patients, suggesting the need to use them in combination with other nutrients.
- Non-patent Document 4 The protein content of the composition described in this document is as high as 3.8 g / 100 kcal, which is difficult to use for patients with restricted protein intake. Furthermore, since the composition does not contain a free amino acid and the selenium and zinc contents are low, their importance is suggested.
- Patent Document 1 discloses a nutritional composition containing protein, fat, carbohydrate, vitamin, mineral, and L-arginine.
- NO nitric oxide
- Patent Document 2 a mixed oil in which the weight ratio of ⁇ -6 fatty acid to ⁇ -3 fatty acid is 0.1 to 3.0, an amino acid containing a branched chain amino acid, ⁇ -carotene, vitamin C, vitamin Compositions for cachexia and / or anorexia patients containing antioxidants such as E and selenium are disclosed.
- a mixed oil in which the weight ratio of ⁇ -6 fatty acid to ⁇ -3 fatty acid is 0.1 to 3.0, an amino acid containing a branched chain amino acid, ⁇ -carotene, vitamin C, vitamin Compositions for cachexia and / or anorexia patients containing antioxidants such as E and selenium are disclosed.
- kidney disease patients unlike healthy subjects, side effects due to large doses of vitamin A and vitamin C are feared, and these contents in this composition are not suitable for kidney disease patients
- Non-Patent Document 5 when soy protein is ingested, the glomerular filtration rate of the kidney It is described that the renal plasma flow rate and the fractional clearance of albumin are reduced, and that the renal vasodilatory effect seen when ingesting animal protein is eliminated, and that the load of soy protein on the kidney is estimated to be small Is done.
- a nutritional composition that has an effective preventive or ameliorating effect on malnutrition, inflammation, arteriosclerosis or lipid metabolism abnormality associated with kidney disease, and is particularly useful for patients with kidney disease.
- the purpose is to do.
- the present inventors have found that one or more free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, ⁇ -3 fatty acids and ⁇ - By containing a lipid containing 6 fatty acids in a specific weight ratio, or by containing soy protein or a hydrolyzate thereof together with or instead of the lipid, malnutrition, inflammation, The present inventors have found that symptoms such as arteriosclerosis and lipid metabolism abnormality can be effectively improved, or that these symptoms can be effectively prevented, and the present invention has been completed.
- the present invention relates to the following [1] to [42].
- [1] One or more free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, ⁇ -3 fatty acids and ⁇ -6 fatty acids, A nutritional composition comprising a lipid that is contained so that the weight ratio of the 6-based fatty acid is 0.5 to 5.5.
- the nutritional composition according to any one of [1] to [7] above comprising a lipid containing 10 to 65% by weight of a medium chain fatty acid oil.
- the nutritional composition according to any one of [1] to [8] above containing 5 mg to 150 mg of vitamin C and / or 1 mg or more of vitamin E per 100 kcal of the composition.
- the nutritional composition according to any one of [1] to [9] above which contains 2.5 ⁇ g to 45 ⁇ g of selenium and 1 mg to 9 mg of zinc per 100 kcal of the composition.
- the nutritional composition according to any one of the above [1] to [10] which is used for patients with renal diseases.
- One or more free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, ⁇ -3 fatty acids and ⁇ -6 fatty acids, It is selected from the group consisting of malnutrition associated with renal disease, inflammation, arteriosclerosis, lipid metabolism abnormality and oxidative stress, which contains lipids such that the weight ratio of 6 fatty acids is 0.5 to 5.5 A preventive or ameliorating agent for one or more symptoms.
- the above [18] or [19] containing 0.1 g to 10 g of one or more free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine per 100 kcal of the composition Preventive or ameliorating agent.
- the content of protein or peptide in a nitrogen source per 100 kcal of the composition is 3.5 g or less, and the content of soy protein or its hydrolyzate in the protein or peptide is 20% by weight to 100% by weight
- the ⁇ -3 fatty acid is one or more fatty acids selected from the group consisting of ⁇ -linolenic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid.
- ⁇ -6 fatty acid is one or more fatty acids selected from the group consisting of linoleic acid, ⁇ -linolenic acid, stearidonic acid, and arachidonic acid.
- Preventive or ameliorating agent [25] The preventive or ameliorating agent according to the above [18] or [19], comprising a lipid containing 10 to 65% by weight of a medium chain fatty acid oil.
- the preventive or ameliorating agent according to the above [18] or [19] containing 5 mg to 150 mg of vitamin C and / or 1 mg or more of vitamin E per 100 kcal of the composition.
- a preventive or ameliorating agent for diabetic nephropathy comprising one or more free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, and soybean protein or a hydrolyzate thereof.
- the content of protein or peptide in the nitrogen source per 100 kcal of the composition is 3.5 g or less, and the content of soy protein or its hydrolyzate in the protein or peptide is 20% by weight to 100% by weight
- the preventive or ameliorating agent according to [28] or [29] above comprising a lipid containing 10 to 65% by weight of a medium chain fatty acid oil.
- the prophylactic or improving agent according to the above [28] or [29] which contains 5 mg to 150 mg of vitamin C and / or 1 mg or more of vitamin E per 100 kcal of the composition.
- the preventive or ameliorating agent according to [28] or [29] above which contains 2.5 ⁇ g to 45 ⁇ g of selenium and 1 mg to 9 mg of zinc per 100 kcal of the composition.
- the nutritional composition according to [1] above is selected from the group consisting of malnutrition associated with renal disease, inflammation, arteriosclerosis, lipid metabolism abnormality, and oxidative stress for patients with renal disease
- a method for preventing or ameliorating one or more symptoms comprising administering an amount sufficient to prevent or ameliorate the above symptoms.
- a composition for diabetic nephropathy comprising administering the nutritional composition according to [1] above to a diabetic nephropathy patient in an amount sufficient to prevent or ameliorate diabetic nephropathy. Prevention or improvement methods.
- the nutritional composition according to [2] above wherein the nutritional composition according to [2] is selected from the group consisting of undernutrition, renal inflammation, arteriosclerosis, lipid metabolism abnormality and oxidative stress associated with renal disease
- a method for preventing or ameliorating one or more symptoms comprising administering an amount sufficient to prevent or ameliorate the above symptoms.
- the nutritional composition according to [2] above comprising administering an amount sufficient to prevent or ameliorate diabetic nephropathy to a diabetic nephropathy patient. Prevention or improvement methods.
- the nutritional composition according to [3] above, wherein the nutritional composition according to [3] is selected from the group consisting of undernutrition, renal inflammation, arteriosclerosis, lipid metabolism abnormality and oxidative stress associated with renal disease A method for preventing or ameliorating one or more symptoms, comprising administering an amount sufficient to prevent or ameliorate the above symptoms.
- a composition for diabetic nephropathy comprising administering the nutritional composition according to [3] above to a patient with diabetic nephropathy in an amount sufficient to prevent or ameliorate diabetic nephropathy. Prevention or improvement methods.
- the nutritional composition according to any one of [1] to [10] above, and the nutritional composition from the group consisting of malnutrition associated with kidney disease, inflammation, arteriosclerosis, lipid metabolism abnormality and oxidative stress A commercial package containing documents that describe or should be used to prevent or ameliorate one or more selected symptoms.
- the nutritional composition according to any one of [1] to [10] above, and the nutritional composition can or should be used for the prevention or improvement of diabetic nephropathy A commercial package containing documents and documents.
- the nutritional composition according to the present invention is useful for patients with renal diseases, and can effectively prevent or improve malnutrition, inflammation, arteriosclerosis, lipid metabolism abnormality, oxidative stress, etc. associated with renal diseases, It is also useful for the prevention or improvement of diabetic nephropathy. Furthermore, the nutritional composition according to the present invention is highly safe and can be continuously used as a nutritional supplement food in patients with renal diseases whose renal function is reduced.
- the nutritional composition according to the present invention comprises one or more free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, an ⁇ -3 fatty acid and an ⁇ -6 fatty acid, And a lipid that is contained so that the weight ratio of ⁇ -6 fatty acid to 3 fatty acid is 0.5 to 5.5. Further, it contains soy protein or a hydrolyzate thereof together with the lipid or in place of the lipid.
- valine, leucine, and isoleucine used in the nutritional composition according to the present invention are amino acids having a branched chain, and play an important role in energy sources during exercise, skeletal muscle maintenance, weight gain, gluconeogenesis, and the like.
- leucine and isoleucine are each known to have an inhibitory effect on postprandial blood glucose elevation.
- Histidine is a basic amino acid that is involved in the active center of enzymes and proton transfer within protein molecules. In proteins, it becomes a binding site with metals, or through hydrogen bonds or ionic bonds. It plays an important role in maintaining its higher-order structure. In the present invention, one or more of these are selected and used. In the present invention, these amino acids are used in a free state.
- any of L-form, D-form and DL-form can be used as valine, leucine, isoleucine and histidine, but L-form is most preferably used.
- L-form is most preferably used.
- amino acid any one of those extracted and purified from animals and plants containing them, or those obtained by chemical synthesis, fermentation, or gene recombination may be used, and commercially available from Sigma-Aldrich. You can also purchase goods.
- these amino acids are more effective when they are contained in an amount of about 0.1 g or more per 100 kcal, and can be increased when a more powerful effect is expected.
- the total content of the composition per 100 kcal is preferably 0.1 g to 10 g, and more preferably 0.2 g to 5 g.
- the ratio of leucine and isoleucine is preferably increased to about 1 to 2.5 times that of valine and histidine.
- ⁇ -3 fatty acids and ⁇ -6 fatty acids are used for ⁇ -3 fatty acids.
- the lipid is contained so that the weight ratio of the ⁇ -6 fatty acid is 0.5 to 5.5.
- ⁇ -3 fatty acid is also referred to as “n-3 fatty acid” and is an unsaturated fatty acid having a double bond third from the methyl group at the end of the hydrocarbon chain, ⁇ -linolenic acid, eicosapentaene
- the acid include docosapentaenoic acid and docosahexaenoic acid. Since eicosapentaenoic acid is known to have an effect of improving insulin resistance, it can be more suitably used in the case of diabetic nephropathy. In the present invention, one or more of these are selected and used.
- ⁇ -6 fatty acid is also expressed as “n-6 fatty acid” and is an unsaturated fatty acid having a sixth double bond from the methyl group at the end of the hydrocarbon chain.
- Linoleic acid, ⁇ -linolenic Examples include acids, stearidonic acid and arachidonic acid. In the present invention, one or more of these are selected and used.
- the ⁇ -3 fatty acid is abundant in perilla oil, linseed oil, fish oil, etc.
- the ⁇ -6 fatty acid is abundant in safflower oil, sunflower oil, soybean oil, rapeseed oil, evening primrose oil, etc.
- These oils and fats can be extracted and purified.
- what was manufactured by the chemical synthesis method, the fermentation method, etc. can also be used, and the commercial item marketed for foodstuffs can also be used.
- the fats and oils rich in ⁇ -3 fatty acids or ⁇ -6 fatty acids can be used as they are as a lipid source.
- the effectiveness of the ⁇ -3 fatty acid and the ⁇ -6 fatty acid used in the present invention is recognized when the weight ratio of the ⁇ -6 fatty acid to the ⁇ -3 fatty acid is 0.5 to 5.5. Accordingly, the lipid is used so that the weight ratio of the ⁇ -6 fatty acid to the ⁇ -3 fatty acid becomes the above weight ratio.
- a more preferred weight ratio is 0.5 to 4, more preferably 0.5 to 3, and particularly preferably 0.5 to 2.
- fats and oils containing ⁇ -3 fatty acid and ⁇ -6 fatty acid in the above weight ratio may be used as they are, and ⁇ -3 fatty acid or fats and oils containing abundantly this , ⁇ -6 fatty acids or fats and oils rich in them may be mixed and used so as to have the above weight ratio.
- the total amount of ⁇ -3 fatty acid and ⁇ -6 fatty acid is preferably 0.5 to 10 g per 100 kcal of the composition according to the present invention.
- the nutritional composition according to the present invention contains one or more free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, and the above ⁇ -3 fatty acid and ⁇ -6 fatty acid.
- soy protein or a hydrolyzate thereof can be further contained.
- the nutritional composition according to the present invention may contain soy protein or a hydrolyzate thereof instead of the lipid containing the ⁇ -3 fatty acid and the ⁇ -6 fatty acid.
- soybean protein separated from soybean by a conventional method can be used. After removing saccharides and the like from defatted soybean obtained by removing soybean oil from whole soybean, and then separating the protein with acid , Neutralized into isolated soy protein, sterilized and dried, prepared by solubilized isolated soy protein, dried and granulated into granules or fibers, isolated soy protein into protease Examples include soybean peptides that have been reduced in molecular weight by the action of enzymes such as In addition, commercial products such as “SUPRO710”, “Fujipro”, “Sun Rubber”, “Prolina”, “Fujinics”, “Apex”, “High New”, “Soya Sour” (all manufactured by Fuji Oil Co., Ltd.) It can also be used. For the purposes of the present invention, those having a low phosphorus concentration are preferred.
- the protein content is not so high, and the total amount of protein or peptide in the nitrogen source per 100 kcal of the composition is preferably 3.5 g or less.
- the protein or peptide preferably contains 20% to 100% by weight of soybean protein or a hydrolyzate thereof.
- the nutritional composition according to the present invention can contain a medium chain fatty acid oil as a lipid source.
- “Medium chain fatty acid” refers to fatty acids having 8 to 10 carbon atoms such as caprylic acid and capric acid
- “medium chain fatty acid oil” refers to fats and oils containing triglycerides of the above medium chain fatty acids.
- Medium-chain fatty acids are generally about 4 times faster in digestion and absorption than long-chain fatty acids present in fats and oils, and after absorption, they are transported to the liver via the portal vein without passing through the lymph vessels, and are rapidly metabolized. Therefore, it can be suitably used as an energy source.
- fats and oils containing a large amount of medium chain fatty acids such as coconut oil, palm oil and palm kernel oil can be used as the medium chain fatty acid oil.
- coconut oil, palm oil, etc. those extracted and purified from natural plants such as coconut may be used, but it is convenient to use commercially available products.
- Vitamins and minerals can also be added to the nutritional composition according to the present invention.
- vitamin A such as retinol, retinal and retinoic acid
- carotenoid such as ⁇ -carotene
- vitamin D such as ergocalciferol and cholecalciferol
- vitamin E such as ⁇ -tocopherol
- vitamin K such as phylloquinone and menaquinone
- Fat-soluble vitamins such as vitamin B 1 such as thiamine, vitamin B 2 such as riboflavin, vitamin B 6 such as pyridoxine, pyridoxal and pyridoxamine, vitamin B 12 such as cyanocobalamin, niacin such as nicotinic acid and nicotinamide, pantothenic acid Vitamin B group such as biotin and folic acid; water-soluble vitamins such as vitamin C.
- the addition of an antioxidant is effective for preventing or improving oxidative stress associated with kidney disease
- the addition of vitamin C and / or vitamin E is preferred in the present invention.
- About vitamin C it is more preferable to contain 15 mg or more.
- Vitamin E is not particularly limited, but it is appropriate that the daily intake for adults is 800 mg or less in terms of ⁇ -tocopherol. Vitamin A is also more likely to accumulate in the body in patients with kidney disease, so the amount added should be taken into consideration, and it is appropriate that the amount be 70 ⁇ g retinol equivalent or less per 100 kcal of the composition.
- the nutritional composition of the present invention As described above, since the importance of selenium and zinc is suggested in the nutritional composition for patients with renal diseases, it is preferable to add an appropriate amount of these in the nutritional composition of the present invention.
- Selenium is considered to be incorporated into a protein in a living body and to be mainly involved in an antioxidant function.
- zinc is necessary for the expression of the activity of enzymes involved in immunity, wound healing, spermatogenesis, taste sensing, and the like.
- the amount of these compositions to be mixed is suitably 2.5 ⁇ g to 45 ⁇ g of selenium and 1 mg to 9 mg of zinc per 100 kcal of the composition in consideration of Japanese dietary intake standards.
- the nutrition composition which concerns on this invention, it is desirable that there is little water content, and 70 g or less is preferable per 100 kcal of this composition.
- Saccharides such as glucose, sucrose and dextrin can be further added to the nutritional composition according to the present invention.
- dietary fibers such as pectin, agarose, glucomannan, cellulose, and poorly soluble dextrin can be added.
- pectin pectin
- agarose agarose
- glucomannan cellulose
- poorly soluble dextrin can be added.
- absorption delaying carbohydrate such as isomaltulose (palatinose).
- the nutritional composition according to the present invention can be easily ingested on a daily basis, it is preferably provided in a form that can be ingested orally.
- one or more free amino acids selected from valine, leucine, isoleucine and histidine, lipids containing ⁇ -3 fatty acids and ⁇ -6 fatty acids, etc. are mixed as they are for nutrition. It can be ingested as a composition, but it can also be formulated as a pharmaceutical with a pharmaceutically acceptable carrier, or provided as a pharmaceutical product, or a food for specified health or nutritional function food with the addition of food or beverage ingredients or food additives It can also be provided as food and drink such as health functional foods such as, dietary supplements, and other health foods.
- liquid preparations such as elixirs, suspensions, syrups, emulsions and ampoules; gels, gums, drops, powders, granules, Solid preparations such as pills, tablets (including sugar-coated tablets and film-coated tablets), capsules, and sachets can be used.
- Pharmaceutically acceptable pharmaceutical carriers that can be used in formulating the nutritional composition according to the present invention include cellulose and its derivatives such as crystalline cellulose and hydroxypropylcellulose; natural polymer compounds such as gum arabic and sodium alginate Excipients such as guar gum, stearic acid, polymeric polyvinylpyrrolidone, etc .; lubricants such as talc and polyethylene glycol 6000; disintegrants such as adipic acid, sucrose fatty acid ester, soybean lecithin, polyoxyethylene cured Surfactants such as castor oil, polyoxyethylene monostearate; thickeners such as sodium carboxymethylcellulose, carboxyvinyl polymer, xanthan gum, gelatin; ethyl acrylate / methyl methacrylate copolymer dispersion, caramel, carnavalo , Shellac, pullulan and other coating agents; citric acid, sodium citrate, acetic acid, sodium acetate, sodium hydroxide and other pH adjusters; ery
- liquid products such as beverages, milky products such as milk, milk beverages, yogurt, jelly-like beverages, jelly-like products such as jelly, gum-like products, powders Product, granule product, sheet product, capsule product, tablet product, snack bar, cookie and other solid products.
- sweeteners coloring agents, preservatives, thickening stabilizers, antioxidants, color formers, bleaching agents
- examples include fungicides, gum bases, bitters, enzymes, brighteners, acidulants, seasonings, emulsifiers, reinforcing agents, manufacturing agents, fragrances, spices and the like.
- the “packaging form of one meal intake unit” is a form in which the amount of food and drink consumed per meal is determined in advance. For example, in the case of beverages, gums, jellies, yogurts, cookies, etc., packs, bags In the case of foods such as granules, powders, slurries, etc., the form in which each intake is individually packaged in packs, bags, etc. Is mentioned.
- the composition according to the present invention is in the form of a unit amount per serving.
- a health functional food such as a nutritional functional food, a nutritional supplement, or other health food
- the composition according to the present invention is in the form of a unit amount per serving. Examples include a packaged form and a form in which a beverage in which the composition according to the present invention is suspended or dissolved is filled in a bottle or the like in the form of a drink per serving.
- the daily intake of the nutritional composition according to the present invention is individually determined according to the age, sex, weight, degree of symptoms associated with kidney disease, degree of decrease in kidney function, dietary condition, etc. However, it is appropriate to take about 50 kcal to 2000 kcal per day for an adult with the nutritional composition of the present invention. It is preferable to take the above-mentioned amount divided into about 1 to 3 times a day.
- the nutritional composition which concerns on this invention into the food-drinks of the packaging form of the unit of 1 meal intake, it packs individually for every intake per time defined by the above.
- the nutrition composition which concerns on this invention has little load with respect to a renal function, it can be made to ingest continuously.
- the nutritional composition according to the present invention is effective for renal diseases because the malnutrition state, inflammation, etc. persist and there is a high risk of developing arteriosclerosis, lipid metabolism abnormality, etc. It is preferable to ingest for a long time until the accompanying improvement of the symptom is recognized.
- the nutritional composition according to the present invention can be produced by a general formulation technique and food production technique.
- the nutritional composition according to the present invention is useful as a pharmaceutical, food or drink for preventing or improving undernutrition associated with kidney disease.
- absorption of fat-soluble vitamins, vitamin B 12 , calcium and iron tends to be inhibited due to poor absorption.
- Patients with kidney disease, including those with dialysis induction, are prone to protein, iron, and vitamin D deficiencies. Protein deficiency causes protein-energy malnutrition, hypoalbuminemia.
- iron deficiency causes iron deficiency anemia
- vitamin D deficiency causes osteomalacia and rickets.
- the nutritional composition according to the present invention can effectively prevent or improve the appearance of the above-mentioned diseases and symptoms by effectively preventing or improving such undernutrition caused by renal diseases.
- the nutritional composition according to the present invention is useful as a pharmaceutical, food or drink for preventing or improving inflammation associated with kidney disease.
- Inflammation associated with kidney disease includes acute nephritis syndrome such as acute glomerulonephritis and post-infection glomerulonephritis; chronic nephritis such as chronic nephritis and slowly progressive glomerular disease; nephrotic syndrome; diabetic nephropathy and the like
- the nutritional composition according to the present invention can effectively prevent or ameliorate such inflammatory symptoms. For example, it is particularly effective for inflammatory symptoms associated with renal diseases having a blood CRP concentration of 0.2 mg / dL or more.
- the nutritional composition according to the present invention is useful as a pharmaceutical, food or drink for the prevention or improvement of arteriosclerosis associated with kidney disease.
- Arteriosclerosis associated with renal disease includes atherosclerosis due to renal failure, which is a particularly problematic symptom in patients with renal disease who have been introduced with dialysis.
- the nutritional composition according to the present invention can effectively prevent the onset of such arteriosclerosis and can effectively improve the symptoms.
- the nutritional composition according to the present invention is useful as a pharmaceutical, food or drink for the prevention or improvement of lipid metabolism abnormalities associated with renal diseases.
- lipid metabolism abnormalities such as LDL cholesterolemia, low high density lipoprotein cholesterolemia, and hypertriglyceridemia is observed.
- VLDL very low density lipoprotein
- the nutritional composition according to the present invention can effectively suppress the onset of lipid metabolism abnormalities such as an increase in blood LDL cholesterol associated with renal diseases, and is useful for the prevention or improvement of lipid metabolic abnormalities associated with renal diseases. .
- the nutritional composition according to the present invention is useful for the prevention or improvement of malnutrition, inflammation, arteriosclerosis and lipid metabolism abnormality associated with renal diseases, and thus prevents the development of MIA syndrome in patients with renal diseases. It is effective in doing. For example, it is particularly effective for dialysis patients whose blood CRP concentration is 0.2 mg / dL or more and albumin concentration is 3.5 g / dL or less. Therefore, it is preferable to ingest the nutritional composition according to the present invention to a renal disease patient who shows signs of MIA syndrome such as decreased appetite, inflammation, and lipid metabolism abnormality.
- the active oxygen and lipid peroxide carried by the blood are concentrated in the kidney.
- oxidative stress causes damage to the renal tissue and, as described above, oxidizes LDL cholesterol to produce lipid peroxide and increases the risk of developing atherosclerosis.
- the nutritional composition according to the present invention is useful as a pharmaceutical, food or drink for preventing or improving such oxidative stress associated with kidney disease.
- the nutrition composition which concerns on this invention contains the vitamin C and vitamin E which are antioxidants, or the selenium which has an antioxidant effect
- the nutritional composition according to the present invention is also useful as a pharmaceutical, food or drink for the prevention or improvement of such diabetic nephropathy.
- leucine or isoleucine is used as the free amino acid, or when eicosapentaenoic acid is used as the ⁇ -3 fatty acid, an effect of suppressing blood sugar elevation after meals and an effect of improving insulin resistance are seen. Can be used.
- one or more free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, ⁇ -3 fatty acid and ⁇ -6 fatty acid are used.
- the preventive or ameliorating agent may further contain soy protein or a hydrolyzate thereof.
- one or two or more free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine and soy protein or a hydrolyzate thereof are contained, resulting in malnutrition associated with kidney disease, inflammation, arteries It can be a preventive or ameliorating agent for one or more symptoms selected from the group consisting of sclerosis, lipid metabolism abnormality and oxidative stress, or a prophylactic or ameliorating agent for diabetic nephropathy.
- Examples of the preventive or ameliorating agent for various symptoms associated with renal diseases or the prophylactic or ameliorating agent for diabetic nephropathy include the above-mentioned medium chain fatty acid oils, vitamins (preferably vitamin C and / or vitamin E), and minerals. (Preferably selenium and zinc), sugar, dietary fiber, and the like can be added.
- the present invention provides each nutritional composition described above with respect to a renal disease patient, one or more selected from the group consisting of undernutrition associated with renal disease, inflammation, arteriosclerosis, lipid metabolism abnormality and oxidative stress.
- the method for preventing or ameliorating one or more of the above symptoms comprising administering an amount sufficient to prevent or ameliorate the symptoms, or preventing or improving diabetic nephropathy for diabetic nephropathy patients
- the present invention provides a method for preventing or ameliorating diabetic nephropathy, comprising administering an amount sufficient to do so.
- diabetic nephropathy Depends on the age, sex, weight, renal disease, the degree of diabetic nephropathy, the degree of decrease in renal function, dietary conditions, etc. of the renal disease patient or diabetic nephropathy patient. Depending on the composition, it is about 50 kcal to 2000 kcal per day for an adult.
- each of the above nutritional compositions and the nutritional composition is selected from the group consisting of malnutrition associated with kidney disease, inflammation, arteriosclerosis, lipid metabolism abnormality and oxidative stress 1 or A commercial package containing each document that states that it can or should be used for the prevention or amelioration of two or more symptoms, or each of the above nutritional compositions, and the nutritional composition is diabetic Commercial packages can be provided that include documents that can be used or should be used for the prevention or amelioration of nephropathy.
- Example 1 Jelly-like beverage for patients with kidney disease Considering the optimal nutritional effect for patients with kidney disease, the nutrient composition shown in Table 1 is assembled, and based on this, a jelly-like beverage is prepared as a nutritional composition according to the present invention. did. That is, each component and thickening polysaccharide were added to water so as to have the composition shown in Table 1, mixed, stirred and emulsified, and after cooling, the pH was adjusted to 3.8. Further, the mixture was sterilized by heating at 80 ° C. for 10 minutes, cooled and filled in a pouch.
- Example 2 Milk drink for kidney disease patients with diabetes Considering the optimal nutritional effect for kidney disease patients with diabetes, the nutrient composition shown in Table 2 was assembled, and based on this, the nutritional composition according to the present invention was constructed.
- a milk drink was prepared. That is, each component and an emulsifier were added to water and mixed so as to have the composition of Table 2, and the emulsification step was repeated a plurality of times under a pressure of 500 to 1,000 kg / cm 2 with a high-pressure emulsifier.
- An emulsified composition was obtained.
- the emulsified composition was filled in an aluminum bag with a normal filling machine and sterilized under normal conditions with a retort sterilizer.
- the milk beverage according to this example had all components stably even after one year, and the viscosity at 25 ° C. was 9 mPa ⁇ s.
- Example 3 Acidic beverage for patients with renal disease requiring restriction on protein intake Considering the optimal nutritional effect for patients with renal disease requiring restriction on protein intake, the nutrient composition shown in Table 3 was assembled, and based on this, the present invention was constructed.
- An acidic beverage was prepared as a nutritional composition according to the above. That is, each component was added to water so as to have the composition shown in Table 3, mixed and stirred, and then the pH was adjusted to 3.8. Furthermore, the mixture was sterilized by heating at 80 ° C. for 10 minutes, cooled and filled into bottles.
- Example 4 Concentrated composition for patients with kidney disease The composition obtained in the same manner as in Example 1 except for vitamins, minerals, carbohydrates and medium chain fatty acids from Example 1 above.
- the composition according to the present example is useful as a health supplement, and can exhibit excellent effects even when added to a general-purpose liquid food.
- CCT in Table 4 refers to 4 wt% cholesterol, 1 wt% cholic acid, and 0.5 wt% thiouracil, and has an action of inducing inflammation of blood vessels similar to arteriosclerosis.
- the increase in body weight was smaller than that in the control (1A) group, but in the 1D group, the 1B group and The increase in body weight was greater than that in the 1C group.
- CRP which is an index of inflammation
- the value of the control (1A) group was increased to 123% and 136%, respectively, when the value was 100%.
- the 1D group fed with a diet containing lipids having a omega-6 fatty acid to omega-3 fatty acid content ratio of 1.6 such an increase in CRP was observed in the control group 1A. It was suppressed to the same level as the value.
- the LDL cholesterol level which is an index of lipid metabolism abnormality such as hyperlipidemia, was remarkably increased in the 1B group and the 1C group, but in the 1D group, it was about 1/2 that of the 1B group and the 1C group. It was only rising.
- the LDL cholesterol level a significant difference was recognized between the 1D group and the 1B group, and between the 1D group and the 1C group (p ⁇ 0.05).
- osmotic pumps of group 2A 1% by weight inactivated serum-containing phosphate buffered saline (PBS) is used as the solvent.
- PBS phosphate buffered saline
- IL-6 is the final dose.
- the 2A group and the 2B group include a protein-free standard purified feed AIN93G (manufactured by Clea Japan Co., Ltd.) and 5% by weight soy protein, and the 2C group further contains 0.5%.
- 3A group of rat normal feed the protein was removed from the standard purified feed AIN93G (manufactured by Clea Japan Co., Ltd.) and the protein content was 2.5% by weight. AIN93G having a content of 20% by weight and the one corrected to have the same calories were used.
- AIN93G having a content of 20% by weight and the one corrected to have the same calories were used.
- a protein content of 3.5 g per 100 kcal and 1.0 g of type are mixed at 2: 3 and freeze-dried.
- a protein having a protein content of 2.5 g per 100 kcal was used.
- the nutritional product R does not contain soy protein, free branched chain amino acids, or the like, and the weight ratio of omega-6 fatty acids to omega-3 fatty acids is 3.4. is there.
- the nutritional composition A according to the present invention shown in Table 9 was used as the feed of the 3C group.
- Blood was collected from the jugular vein after feeding the same amount of the above-mentioned feed to each group, and was collected from the jugular vein, followed by CRP, IL-6 as an inflammatory index and leukocyte count as a peripheral blood item, neutrophil count, For the albumin / globulin (A / G) ratio, which is an index of serum protein and the like, the amount in plasma was quantified. The results are shown in Table 10.
- the present invention can effectively prevent or improve malnutrition, inflammation, arteriosclerosis, lipid metabolism abnormality, oxidative stress, etc. associated with renal disease for patients with renal disease, and diabetes. It is intended to provide a nutritional composition that is also useful for preventing or improving nephropathy. Furthermore, the present invention provides a nutritional composition that can be continuously used as a food for nutritional supplement even in patients with renal diseases who have high safety and reduced renal function.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
[1]バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、ω-3系脂肪酸とω-6系脂肪酸とを、ω-3系脂肪酸に対するω-6系脂肪酸の重量比が0.5~5.5となるように含有する脂質とを含有する、栄養組成物。
[2]さらに大豆タンパク質又はその加水分解物を含有する、上記[1]に記載の栄養組成物。
[3]バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、大豆タンパク質又はその加水分解物を含有する、栄養組成物。
[4]バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸を、組成物100kcalあたり0.1g~10g含有する、上記[1]~[3]のいずれかに記載の栄養組成物。
[5]組成物100kcalあたりの窒素源中におけるタンパク質又はペプチドの含有量が3.5g以下であり、且つ該タンパク質又はペプチドにおける大豆タンパク質又はその加水分解物の含有量が20重量%~100重量%である、上記[2]~[4]のいずれかに記載の栄養組成物。
[6]ω-3系脂肪酸が、α-リノレン酸、エイコサペンタエン酸、ドコサペンタエン酸及びドコサヘキサエン酸よりなる群から選ばれる1種又は2種以上の脂肪酸である、上記[1]又は[2]に記載の栄養組成物。
[7]ω-6系脂肪酸が、リノール酸、γ-リノレン酸、ステアリドン酸及びアラキドン酸よりなる群から選ばれる1種又は2種以上の脂肪酸である、上記[1]、[2]又は[6]のいずれかに記載の栄養組成物。
[8]中鎖脂肪酸油を10重量%~65重量%含有する脂質を含有する、上記[1]~[7]のいずれかに記載の栄養組成物。
[9]組成物100kcalあたりにおいて、ビタミンCを5mg~150mg、及び/又はビタミンEを1mg以上含有する、上記[1]~[8]のいずれかに記載の栄養組成物。
[10]組成物100kcalあたりにおいて、セレンを2.5μg~45μg、及び亜鉛を1mg~9mg含有する、上記[1]~[9]のいずれかに記載の栄養組成物。
[11]腎疾患患者用である、上記[1]~[10]のいずれかに記載の栄養組成物。
[12]腎疾患に伴う低栄養状態の予防又は改善用である、上記[1]~[10]のいずれかに記載の栄養組成物。
[13]腎疾患に伴う炎症の予防又は改善用である、上記[1]~[10]のいずれかに記載の栄養組成物。
[14]腎疾患に伴う動脈硬化の予防又は改善用である、上記[1]~[10]のいずれかに記載の栄養組成物。
[15]腎疾患に伴う脂質代謝異常の予防又は改善用である、上記[1]~[10]のいずれかに記載の栄養組成物。
[16]腎疾患に伴う酸化ストレスの予防又は改善用である、上記[1]~[10]のいずれかに記載の栄養組成物。
[17]糖尿病性腎症の予防又は改善用である、上記[1]~[10]のいずれかに記載の栄養組成物。
[18]バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、ω-3系脂肪酸とω-6系脂肪酸とを、ω-3系脂肪酸に対するω-6系脂肪酸の重量比が0.5~5.5となるように含有する脂質とを含有する、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状の予防又は改善剤。
[19]バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、ω-3系脂肪酸とω-6系脂肪酸とを、ω-3系脂肪酸に対するω-6系脂肪酸の重量比が0.5~5.5となるように含有する脂質とを含有する、糖尿病性腎症の予防又は改善剤。
[20]さらに大豆タンパク質又はその加水分解物を含有する、上記[18]又は[19]に記載の予防又は改善剤。
[21]バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸を、組成物100kcalあたり0.1g~10g含有する、上記[18]又は[19]に記載の予防又は改善剤。
[22]組成物100kcalあたりの窒素源中におけるタンパク質又はペプチドの含有量が3.5g以下であり、且つ該タンパク質又はペプチドにおける大豆タンパク質又はその加水分解物の含有量が20重量%~100重量%である、上記[20]に記載の予防又は改善剤。
[23]ω-3系脂肪酸が、α-リノレン酸、エイコサペンタエン酸、ドコサペンタエン酸及びドコサヘキサエン酸よりなる群から選ばれる1種又は2種以上の脂肪酸である、上記[18]又は[19]に記載の予防又は改善剤。
[24]ω-6系脂肪酸が、リノール酸、γ-リノレン酸、ステアリドン酸及びアラキドン酸よりなる群から選ばれる1種又は2種以上の脂肪酸である、上記[18]又は[19]に記載の予防又は改善剤。
[25]中鎖脂肪酸油を10重量%~65重量%含有する脂質を含有する、上記[18]又は[19]に記載の予防又は改善剤。
[26]組成物100kcalあたりにおいて、ビタミンCを5mg~150mg、及び/又はビタミンEを1mg以上含有する、上記[18]又は[19]に記載の予防又は改善剤。
[27]組成物100kcalあたりにおいて、セレンを2.5μg~45μg、及び亜鉛を1mg~9mg含有する、上記[18]又は[19]に記載の予防又は改善剤。
[28]バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、大豆タンパク質又はその加水分解物を含有する、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状の予防又は改善剤。
[29]バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、大豆タンパク質又はその加水分解物を含有する、糖尿病性腎症の予防又は改善剤。
[30]バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸を、組成物100kcalあたり0.1g~10g含有する、上記[28]又は[29]に記載の予防又は改善剤。
[31]組成物100kcalあたりの窒素源中におけるタンパク質又はペプチドの含有量が3.5g以下であり、且つ該タンパク質又はペプチドにおける大豆タンパク質又はその加水分解物の含有量が20重量%~100重量%である、上記[28]又は[29]に記載の予防又は改善剤。
[32]中鎖脂肪酸油を10重量%~65重量%含有する脂質を含有する、上記[28]又は[29]に記載の予防又は改善剤。
[33]組成物100kcalあたりにおいて、ビタミンCを5mg~150mg、及び/又はビタミンEを1mg以上含有する、上記[28]又は[29]に記載の予防又は改善剤。
[34]組成物100kcalあたりにおいて、セレンを2.5μg~45μg、及び亜鉛を1mg~9mg含有する、上記[28]又は[29]に記載の予防又は改善剤。
[35]上記[1]に記載の栄養組成物を、腎疾患患者に対して、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状を予防又は改善するのに十分な量を投与することを含む、前記1又は2以上の症状の予防又は改善方法。
[36]上記[1]に記載の栄養組成物を、糖尿病性腎症患者に対して、糖尿病性腎症を予防又は改善するのに十分な量を投与することを含む、糖尿病性腎症の予防又は改善方法。
[37]上記[2]に記載の栄養組成物を、腎疾患患者に対して、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状を予防又は改善するのに十分な量を投与することを含む、前記1又は2以上の症状の予防又は改善方法。
[38]上記[2]に記載の栄養組成物を、糖尿病性腎症患者に対して、糖尿病性腎症を予防又は改善するのに十分な量を投与することを含む、糖尿病性腎症の予防又は改善方法。
[39]上記[3]に記載の栄養組成物を、腎疾患患者に対して、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状を予防又は改善するのに十分な量を投与することを含む、前記1又は2以上の症状の予防又は改善方法。
[40]上記[3]に記載の栄養組成物を、糖尿病性腎症患者に対して、糖尿病性腎症を予防又は改善するのに十分な量を投与することを含む、糖尿病性腎症の予防又は改善方法。
[41]上記[1]~[10]のいずれかに記載の栄養組成物と、当該栄養組成物を腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状の予防もしくは改善のために使用し得るか、又は使用すべきであることを記載した書類とを含む、商業的パッケージ。
[42]上記[1]~[10]のいずれかに記載の栄養組成物と、当該栄養組成物を糖尿病性腎症の予防もしくは改善のために使用し得るか、又は使用すべきであることを記載した書類とを含む、商業的パッケージ。
腎疾患患者に対する最適栄養効果を考慮して、表1に示す栄養素組成を組み立て、これに基づき、本発明に係る栄養組成物としてゼリー様飲料を調製した。すなわち、表1の組成となるように、各成分と増粘多糖類を水に添加し、混合、撹拌して乳化し、冷却後pHを3.8とした。さらに、80℃で10分間加熱滅菌し、冷却してパウチに充填した。
糖尿病を伴う腎疾患患者に対する最適栄養効果を考慮して、表2に示す栄養素組成を組み立て、これに基づき、本発明に係る栄養組成物として乳飲料を調製した。すなわち、表2の組成となるように、各成分と乳化剤を水に添加して混合し、高圧乳化機にて、500~1,000kg/cm2の加圧下にて複数回乳化工程を繰り返し、乳化組成物を得た。この乳化組成物を、通常の充填機にてアルミ製の袋に充填し、レトルト殺菌機にて通常の条件下に滅菌した。本実施例に係る乳飲料は、1年後においても全成分は安定に存在し、25℃における粘度は9mPa・sであった。
タンパク質摂取制限の必要な腎疾患患者に対する最適栄養効果を考慮して、表3に示す栄養素組成を組み立て、これに基づき、本発明に係る栄養組成物として酸性飲料を調製した。すなわち、表3の組成となるように、各成分を水に添加し、混合、撹拌した後pHを3.8とした。さらに、80℃で10分間加熱滅菌し、冷却してボトルに充填した。
上記実施例1より、ビタミン類、ミネラル類、糖質及び中鎖脂肪酸を除いて、実施例1と同様に調製して得た。本実施例に係る組成物は、健康補助食品として有用であり、また汎用流動食に添加しても優れた効果を発揮し得るものである。
本発明に係る栄養組成物において脂質源として用いる不飽和脂肪酸について、ω-3系脂肪酸に対するω-6系脂肪酸の含有重量比が、低栄養状態や炎症等の予防、改善効果に及ぼす影響を、以下の実験により検討した。すなわち、6週齢のSD系雄性ラットを4群に分け(各群n=6)、それぞれ表4に示す組成の脂質を含有し、脂質以外は標準精製飼料AIN93G(日本クレア株式会社製)に準じて調製した飼料を等量ずつ2週間摂取させた。その後頸静脈より採血し、血漿中のCRP濃度及びLDLコレステロール濃度を常法により定量した。試験結果を表5に示した。
透析患者において、炎症性サイトカインであるインターロイキン(IL)-6の血中レベルが健常人に比べて高いことが知られている。そこで、本発明で用いる遊離のアミノ酸がIL-6に由来する炎症に及ぼす影響を検討するため、以下の実験を行った。すなわち、6週齢のSD系雄性ラットに浸透圧ポンプ(流速240μL/day)を腰背中部皮下に埋め込み、3群(各群n=5)に分けた。2A群の浸透圧ポンプには、溶媒である1重量%非働化血清含有リン酸緩衝生理食塩水(PBS)を、2B群および2C群の浸透圧ポンプには、IL-6を最終の投与量が400μg/日/kgラットとなるように充填した。また表6に示すように、2A群及び2B群には無タンパク質の標準精製飼料AIN93G(日本クレア株式会社製)に5重量%の大豆タンパク質を配合したものを、2C群にはさらに0.5重量%(0.13g/100kcal)の遊離のアミノ酸(バリン:ロイシン:イソロイシン=1.2:2:1)を配合したものを、飼料としてそれぞれ1週間自由に摂取させた。なお、各群に摂取させる飼料は、コーンスターチにより各群の摂取カロリーが等しくなるように補正した。その後、麻酔下にて腹大静脈下より採血し、血漿中のCRP濃度を常法により定量した。結果を表7に示す。
次いで、本発明に係る栄養組成物において脂質源として用いる不飽和脂肪酸について、ω-3系脂肪酸に対するω-6系脂肪酸の含有重量比、本発明で用いる遊離のアミノ酸及び大豆タンパク質が、腎疾患に伴う炎症の各指標値に及ぼす影響について検討した。本試験においては、6週齢のSD系雄性ラットに偽手術又は腎臓の5/6を摘出する手術を行い、1週間の回復期間の後、表8に示す3群(各群n=7)に分けた。3A群のラット通常飼料としては、標準精製飼料AIN93G(日本クレア株式会社製)よりタンパク質を除いたものに、タンパク質含量が2.5重量%となるように乳タンパク質のみを配合し、コーンスターチでタンパク質含量が20重量%であるAIN93Gとカロリーが等しくなるように補正したものを用いた。また、3B群に摂取させた市販の腎疾患患者用栄養製品Rとしては、タンパク質含量が100kcal当たり3.5gのタイプと1.0gのタイプを2:3で混合し、凍結乾燥させることにより、タンパク質含量が100kcal当たり2.5gとなるように調製したものを用いた。栄養製品Rには、表9に示されるように、大豆タンパク質や遊離の分岐鎖アミノ酸等は配合されておらず、ω-3系脂肪酸に対するω-6系脂肪酸の含有重量比は3.4である。また3C群の飼料としては、表9に示す本発明に係る栄養組成物Aを用いた。なお、3B群と3C群の飼料には、上記CCT(コレステロール:コール酸:チオウラシル=8:2:1)を試験食100kcal当たり1.46g配合した。各群に等量の前記飼料を与えて2週間飼育した後頚静脈より採血し、常法により、炎症性指標であるCRP、IL-6及び末梢血項目である白血球数、好中球数、血清タンパク質等の指標であるアルブミン/グロブリン(A/G)比について、血漿中量の定量を行った。その結果を表10に示した。
Claims (30)
- バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、ω-3系脂肪酸とω-6系脂肪酸とを、ω-3系脂肪酸に対するω-6系脂肪酸の重量比が0.5~5.5となるように含有する脂質とを含有する、栄養組成物。
- さらに大豆タンパク質又はその加水分解物を含有する、請求項1に記載の栄養組成物。
- バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、大豆タンパク質又はその加水分解物を含有する、栄養組成物。
- バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸を、組成物100kcalあたり0.1g~10g含有する、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 組成物100kcalあたりの窒素源中におけるタンパク質又はペプチドの含有量が3.5g以下であり、且つ該タンパク質又はペプチドにおける大豆タンパク質又はその加水分解物の含有量が20重量%~100重量%である、請求項2又は請求項3に記載の栄養組成物。
- ω-3系脂肪酸が、α-リノレン酸、エイコサペンタエン酸、ドコサペンタエン酸及びドコサヘキサエン酸よりなる群から選ばれる1種又は2種以上の脂肪酸である、請求項1又は請求項2に記載の栄養組成物。
- ω-6系脂肪酸が、リノール酸、γ-リノレン酸、ステアリドン酸及びアラキドン酸よりなる群から選ばれる1種又は2種以上の脂肪酸である、請求項1又は請求項2に記載の栄養組成物。
- 中鎖脂肪酸油を10重量%~65重量%含有する脂質を含有する、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 組成物100kcalあたりにおいて、ビタミンCを5mg~150mg、及び/又はビタミンEを1mg以上含有する、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 組成物100kcalあたりにおいて、セレンを2.5μg~45μg、及び亜鉛を1mg~9mg含有する、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 腎疾患患者用である、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 腎疾患に伴う低栄養状態の予防又は改善用である、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 腎疾患に伴う炎症の予防又は改善用である、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 腎疾患に伴う動脈硬化の予防又は改善用である、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 腎疾患に伴う脂質代謝異常の予防又は改善用である、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 腎疾患に伴う酸化ストレスの予防又は改善用である、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- 糖尿病性腎症の予防又は改善用である、請求項1~請求項3のいずれか1項に記載の栄養組成物。
- バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、ω-3系脂肪酸とω-6系脂肪酸とを、ω-3系脂肪酸に対するω-6系脂肪酸の重量比が0.5~5.5となるように含有する脂質とを含有する、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状の予防又は改善剤。
- バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、ω-3系脂肪酸とω-6系脂肪酸とを、ω-3系脂肪酸に対するω-6系脂肪酸の重量比が0.5~5.5となるように含有する脂質とを含有する、糖尿病性腎症の予防又は改善剤。
- さらに大豆タンパク質又はその加水分解物を含有する、請求項18又は請求項19に記載の予防又は改善剤。
- バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、大豆タンパク質又はその加水分解物を含有する、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状の予防又は改善剤。
- バリン、ロイシン、イソロイシン及びヒスチジンよりなる群から選ばれる1種又は2種以上の遊離のアミノ酸と、大豆タンパク質又はその加水分解物を含有する、糖尿病性腎症の予防又は改善剤。
- 請求項1に記載の栄養組成物を、腎疾患患者に対して、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状を予防又は改善するのに十分な量を投与することを含む、前記1又は2以上の症状の予防又は改善方法。
- 請求項1に記載の栄養組成物を、糖尿病性腎症患者に対して、糖尿病性腎症を予防又は改善するのに十分な量を投与することを含む、糖尿病性腎症の予防又は改善方法。
- 請求項2に記載の栄養組成物を、腎疾患患者に対して、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状を予防又は改善するのに十分な量を投与することを含む、前記1又は2以上の症状の予防又は改善方法。
- 請求項2に記載の栄養組成物を、糖尿病性腎症患者に対して、糖尿病性腎症を予防又は改善するのに十分な量を投与することを含む、糖尿病性腎症の予防又は改善方法。
- 請求項3に記載の栄養組成物を、腎疾患患者に対して、腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状を予防又は改善するのに十分な量を投与することを含む、前記1又は2以上の症状の予防又は改善方法。
- 請求項3に記載の栄養組成物を、糖尿病性腎症患者に対して、糖尿病性腎症を予防又は改善するのに十分な量を投与することを含む、糖尿病性腎症の予防又は改善方法。
- 請求項1~請求項3のいずれか1項に記載の栄養組成物と、当該栄養組成物を腎疾患に伴う低栄養状態、炎症、動脈硬化、脂質代謝異常及び酸化ストレスよりなる群から選ばれる1又は2以上の症状の予防もしくは改善のために使用し得るか、又は使用すべきであることを記載した書類とを含む、商業的パッケージ。
- 請求項1~請求項3のいずれか1項に記載の栄養組成物と、当該栄養組成物を糖尿病性腎症の予防もしくは改善のために使用し得るか、又は使用すべきであることを記載した書類とを含む、商業的パッケージ。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09830480T ES2745849T3 (es) | 2008-12-05 | 2009-12-04 | Composición nutricional |
CN200980148620.7A CN102238947B (zh) | 2008-12-05 | 2009-12-04 | 营养组合物 |
JP2010541375A JP5950292B2 (ja) | 2008-12-05 | 2009-12-04 | 栄養組成物 |
EP09830480.1A EP2374452B1 (en) | 2008-12-05 | 2009-12-04 | Nutrient composition |
US13/152,574 US9629386B2 (en) | 2008-12-05 | 2011-06-03 | Nutrition composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008310955 | 2008-12-05 | ||
JP2008-310955 | 2008-12-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/152,574 Continuation US9629386B2 (en) | 2008-12-05 | 2011-06-03 | Nutrition composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010064714A1 true WO2010064714A1 (ja) | 2010-06-10 |
Family
ID=42233361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/070432 WO2010064714A1 (ja) | 2008-12-05 | 2009-12-04 | 栄養組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9629386B2 (ja) |
EP (1) | EP2374452B1 (ja) |
JP (1) | JP5950292B2 (ja) |
CN (1) | CN102238947B (ja) |
ES (1) | ES2745849T3 (ja) |
PT (1) | PT2374452T (ja) |
WO (1) | WO2010064714A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012141316A1 (ja) * | 2011-04-13 | 2012-10-18 | 味の素株式会社 | 栄養組成物 |
JP2013143916A (ja) * | 2012-01-13 | 2013-07-25 | Morinaga Milk Ind Co Ltd | 腎疾患患者用の液状栄養組成物 |
JP2013198444A (ja) * | 2012-03-26 | 2013-10-03 | Kobayashi Pharmaceutical Co Ltd | 長命草及び魚介油を含む組成物 |
WO2014003116A1 (ja) * | 2012-06-28 | 2014-01-03 | 株式会社明治 | 栄養組成物 |
WO2015037655A1 (ja) * | 2013-09-13 | 2015-03-19 | 株式会社明治 | タンパク質の異化軽減または同化促進のための剤 |
US10130603B2 (en) | 2013-11-05 | 2018-11-20 | Colgate-Palmolive Company | Methods and compositions for improving kidney function |
EP2374452B1 (en) | 2008-12-05 | 2019-07-24 | Ajinomoto Co., Inc. | Nutrient composition |
JP2019534329A (ja) * | 2016-11-04 | 2019-11-28 | アイエムエムディー エスペー.ゾー.オー | 摂取および吸収された分子の知的送達 |
EP2670262B1 (en) | 2011-02-02 | 2021-06-30 | Société des Produits Nestlé S.A. | High protein nutritional compositions and methods of making and using same |
JP2022504702A (ja) * | 2018-11-02 | 2022-01-13 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103284040A (zh) * | 2013-05-31 | 2013-09-11 | 烟台燕园科玛生物技术开发有限公司 | 一种增强人体免疫功能的营养粉 |
WO2015105437A1 (en) * | 2014-01-13 | 2015-07-16 | Ockerman Per-Arne | Multi nutrient supplementation |
CN104705659B (zh) * | 2015-04-01 | 2016-08-24 | 邱夏 | 富含欧米伽3酸和支链氨基酸的速溶蛋白粉及制备方法 |
CN106072533A (zh) * | 2016-06-18 | 2016-11-09 | 江苏阜丰生物科技有限公司 | 一种供糖尿病患者食用的全营养配方食品 |
CN106262938A (zh) * | 2016-08-02 | 2017-01-04 | 乐康珍泰(天津)生物技术有限公司 | 一种用于增强体力的组合物及其制备方法 |
WO2018163716A1 (ja) * | 2017-03-08 | 2018-09-13 | 日清オイリオグループ株式会社 | 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物 |
CN107997182A (zh) * | 2017-11-02 | 2018-05-08 | 上海市杨浦区市东医院 | 一种肾衰竭透析患者使用的固定营养剂 |
WO2019118519A1 (en) | 2017-12-11 | 2019-06-20 | Filtricine, Inc. | Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy |
US11738061B2 (en) | 2018-03-05 | 2023-08-29 | Pure Care Pro Llc | Natural combination products and methods for regulation of kidney and excretory system function |
US11666593B2 (en) | 2019-09-05 | 2023-06-06 | Tsi Group, Co. Ltd | Compositions containing adenosine triphosphate (ATP) and methods of use |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0873351A (ja) * | 1994-06-30 | 1996-03-19 | Ajinomoto Co Inc | 炎症性腸疾患用栄養組成物 |
JPH11508282A (ja) | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | 悪液質および食欲不振の予防および治療方法 |
JP2001288107A (ja) * | 2000-04-10 | 2001-10-16 | Snow Brand Milk Prod Co Ltd | 癌化学療法に伴う副作用軽減剤 |
JP2002514575A (ja) | 1998-05-13 | 2002-05-21 | ノバルテイス・ニユートリシヨン・アクチエンゲゼルシヤフト | 腎不全患者用の栄養製品 |
WO2005094813A1 (ja) | 2004-03-31 | 2005-10-13 | Ajinomoto Co., Inc. | 腎疾患用薬剤 |
JP2006503105A (ja) * | 2002-09-20 | 2006-01-26 | ノバルティス アクチエンゲゼルシャフト | ロイシンに富んだ栄養的組成物 |
JP2006520335A (ja) * | 2003-03-18 | 2006-09-07 | ノバルティス アクチエンゲゼルシャフト | 脂肪酸とアミノ酸を含有する組成物 |
JP2008528475A (ja) * | 2005-01-24 | 2008-07-31 | プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ | アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、dhaを含有する脂肪酸組成物の使用 |
JP2008247896A (ja) * | 2007-03-07 | 2008-10-16 | Shizuokaken Koritsu Daigaku Hojin | 透析患者用経口アミノ酸組成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
EP0689835A3 (en) | 1994-06-30 | 1996-04-17 | Ajinomoto Kk | Composition containing an amino acid mixture and at least one N-3 fatty acid |
US5728678A (en) | 1995-06-06 | 1998-03-17 | Nestec Ltd. | Method and composition for providing nutrition to a renal failure patient |
EP1358878A1 (en) * | 2001-01-30 | 2003-11-05 | Ajinomoto Co., Inc. | Remedies/preventives for inflammatory diseases |
WO2002069964A1 (en) * | 2001-03-05 | 2002-09-12 | Ernest Stephen P | Enteral formulation |
US7744930B2 (en) * | 2002-11-22 | 2010-06-29 | Shaklee Corporation | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass |
US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
GB0612671D0 (en) * | 2006-06-27 | 2006-08-09 | Shs Int Ltd | Nutritional formulation |
WO2009157759A1 (en) | 2008-06-23 | 2009-12-30 | N.V. Nutricia | Nutritional composition for improving the mammalian immune system |
WO2010002242A1 (en) | 2008-07-02 | 2010-01-07 | N.V. Nutricia | Nutritional composition for improving muscle function and daily activity |
JP5950292B2 (ja) | 2008-12-05 | 2016-07-13 | 味の素株式会社 | 栄養組成物 |
-
2009
- 2009-12-04 JP JP2010541375A patent/JP5950292B2/ja active Active
- 2009-12-04 PT PT98304801T patent/PT2374452T/pt unknown
- 2009-12-04 EP EP09830480.1A patent/EP2374452B1/en active Active
- 2009-12-04 CN CN200980148620.7A patent/CN102238947B/zh active Active
- 2009-12-04 WO PCT/JP2009/070432 patent/WO2010064714A1/ja active Application Filing
- 2009-12-04 ES ES09830480T patent/ES2745849T3/es active Active
-
2011
- 2011-06-03 US US13/152,574 patent/US9629386B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0873351A (ja) * | 1994-06-30 | 1996-03-19 | Ajinomoto Co Inc | 炎症性腸疾患用栄養組成物 |
JPH11508282A (ja) | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | 悪液質および食欲不振の予防および治療方法 |
JP2002514575A (ja) | 1998-05-13 | 2002-05-21 | ノバルテイス・ニユートリシヨン・アクチエンゲゼルシヤフト | 腎不全患者用の栄養製品 |
JP2001288107A (ja) * | 2000-04-10 | 2001-10-16 | Snow Brand Milk Prod Co Ltd | 癌化学療法に伴う副作用軽減剤 |
JP2006503105A (ja) * | 2002-09-20 | 2006-01-26 | ノバルティス アクチエンゲゼルシャフト | ロイシンに富んだ栄養的組成物 |
JP2006520335A (ja) * | 2003-03-18 | 2006-09-07 | ノバルティス アクチエンゲゼルシャフト | 脂肪酸とアミノ酸を含有する組成物 |
WO2005094813A1 (ja) | 2004-03-31 | 2005-10-13 | Ajinomoto Co., Inc. | 腎疾患用薬剤 |
JP2008528475A (ja) * | 2005-01-24 | 2008-07-31 | プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ | アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、dhaを含有する脂肪酸組成物の使用 |
JP2008247896A (ja) * | 2007-03-07 | 2008-10-16 | Shizuokaken Koritsu Daigaku Hojin | 透析患者用経口アミノ酸組成物 |
Non-Patent Citations (10)
Title |
---|
"An overview of regular dialysis treatment in Japan", THE JAPANESE SOCIETY FOR DIALYSIS THERAPY, 31 December 2007 (2007-12-31), pages 51 - 73 |
AM. J. CLIN. NUTR., vol. 87, 2008, pages 1860 - 1866 |
J. RENAL NUTRITION, vol. 15, no. 2, 2005, pages 253 - 256 |
J. RENAL NUTRITION, vol. 15, no. 3, 2005, pages 318 - 331 |
JOLLY, C.A. ET AL.: "Life span is prolonged in food-restricted autoimmune-prone (NZB x NZW)F(l) mice fed a diet enriched with (n-3) fatty acids", J NUTR, vol. 131, no. 10, 2001, pages 2753 - 2760, XP008166556 * |
KIDNEY INT., vol. 38, 1990, pages 136 - 144 |
LEFKOWITH, J.B. ET AL.: "Polyunsaturated fatty acids and renal disease", PROC SOC EXP BIOL MED, vol. 213, no. 1, 1996, pages 13 - 23, XP008166576 * |
NEPHROL. DIAL. TRANSPLANT., vol. 22, no. 12, 2007, pages 3561 - 3567 |
SAIFULLAH, A. ET AL.: "Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients-a pilot study", NEPHROL DIAL TRANSPLANT, vol. 22, no. 12, 2007, pages 3561 - 3567, XP008166559 * |
See also references of EP2374452A4 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2374452B1 (en) | 2008-12-05 | 2019-07-24 | Ajinomoto Co., Inc. | Nutrient composition |
EP2670262B1 (en) | 2011-02-02 | 2021-06-30 | Société des Produits Nestlé S.A. | High protein nutritional compositions and methods of making and using same |
US10136669B2 (en) | 2011-04-13 | 2018-11-27 | Ajinomoto Co., Inc. | Method for decreasing visceral fat or increasing energy consumption |
CN103458891A (zh) * | 2011-04-13 | 2013-12-18 | 味之素株式会社 | 营养组合物 |
JPWO2012141316A1 (ja) * | 2011-04-13 | 2014-07-28 | 味の素株式会社 | 栄養組成物 |
JP5983601B2 (ja) * | 2011-04-13 | 2016-08-31 | 味の素株式会社 | 栄養組成物 |
WO2012141316A1 (ja) * | 2011-04-13 | 2012-10-18 | 味の素株式会社 | 栄養組成物 |
JP2013143916A (ja) * | 2012-01-13 | 2013-07-25 | Morinaga Milk Ind Co Ltd | 腎疾患患者用の液状栄養組成物 |
JP2013198444A (ja) * | 2012-03-26 | 2013-10-03 | Kobayashi Pharmaceutical Co Ltd | 長命草及び魚介油を含む組成物 |
WO2014003116A1 (ja) * | 2012-06-28 | 2014-01-03 | 株式会社明治 | 栄養組成物 |
JPWO2015037655A1 (ja) * | 2013-09-13 | 2017-03-02 | 株式会社明治 | タンパク質の異化軽減または同化促進のための剤 |
WO2015037655A1 (ja) * | 2013-09-13 | 2015-03-19 | 株式会社明治 | タンパク質の異化軽減または同化促進のための剤 |
US10130603B2 (en) | 2013-11-05 | 2018-11-20 | Colgate-Palmolive Company | Methods and compositions for improving kidney function |
JP2019534329A (ja) * | 2016-11-04 | 2019-11-28 | アイエムエムディー エスペー.ゾー.オー | 摂取および吸収された分子の知的送達 |
US11696920B2 (en) | 2016-11-04 | 2023-07-11 | Immd Sp. Zo.O | Intelligent delivery of ingested and absorbed molecules |
JP2022504702A (ja) * | 2018-11-02 | 2022-01-13 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 |
JP7542530B2 (ja) | 2018-11-02 | 2024-08-30 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 |
Also Published As
Publication number | Publication date |
---|---|
ES2745849T3 (es) | 2020-03-03 |
PT2374452T (pt) | 2019-10-31 |
JPWO2010064714A1 (ja) | 2012-05-10 |
EP2374452B1 (en) | 2019-07-24 |
CN102238947B (zh) | 2015-01-14 |
JP5950292B2 (ja) | 2016-07-13 |
EP2374452A1 (en) | 2011-10-12 |
US20110288012A1 (en) | 2011-11-24 |
CN102238947A (zh) | 2011-11-09 |
US9629386B2 (en) | 2017-04-25 |
EP2374452A4 (en) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5950292B2 (ja) | 栄養組成物 | |
US10136669B2 (en) | Method for decreasing visceral fat or increasing energy consumption | |
AU2004222633B2 (en) | Compositions comprising fatty acids and amino acids | |
EP2528456B1 (en) | Liquid enteral nutritional composition suitable for tube feeding | |
JP5574561B2 (ja) | 総合経腸栄養組成物 | |
JP6346896B2 (ja) | カルシウムβ−ヒドロキシ−β−メチルブチレート、タンパク質および低レベルの電解質を含む栄養組成物 | |
US20090238893A1 (en) | Nutritional formulation | |
US10064835B2 (en) | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers | |
JP2012019691A (ja) | 腎疾患患者用経口栄養組成物 | |
US11122833B1 (en) | Infant formulas having vitamin complexes with enhanced bioavailability | |
JP3102645B2 (ja) | 栄養補給用栄養組成物 | |
WO2022025231A1 (ja) | 栄養製剤 | |
WO2012133198A1 (ja) | 炎症性疾患用栄養組成物 | |
RU2605198C2 (ru) | Способ для снижения распространения инфекции у детей младшего возраста | |
WO2023282316A1 (ja) | 経腸栄養製剤 | |
US20230140497A1 (en) | Nutritional composition for renal support |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980148620.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09830480 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2010541375 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009830480 Country of ref document: EP |